BACKGROUND: Because resolution of symptoms is a primary goal of antimicrobial therapy in children with acute otitis media (AOM), measurement of symptoms in studies of antimicrobial effectiveness in such children is important. We have developed a scale for measuring symptoms of AOM in young children (AOM-SOS), and we present data on its construct validity and responsiveness. METHODS: We followed children 3 months to 3 years of age with AOM, who were receiving antimicrobial treatment, using the AOM-SOS scale. The scale was administered at the enrollment visit, as a twice-a-day diary measure, and at the follow-up visit (days 5-7). To evaluate construct validity, we examined the correlation, at entry, between AOM-SOS scores and scores on other measures of pain and functional status. To evaluate the scale's responsiveness, we examined the change in scale scores from entry to follow-up. We also examined the levels of agreement between the scale scores and overall assessments of the children by parents. RESULTS: We enrolled 70 children (mean age 12.5 months) of whom 57 returned for follow-up. The magnitude of the correlations between the AOM-SOS scale scores and other measures of pain and functional status ranged from 0.56 to 0.84. The responsiveness of the AOM-SOS, as measured by the standardized response mean was 1.20. CONCLUSIONS: These data support the validity and responsiveness of the AOM-SOS; the scale seems to measure effectively both pain and overall functional status in young children with AOM. Changes in score over the first few days of illness were substantial and generally matched the assessments both of parents and of clinicians. The AOM-SOS promises to be useful as an outcome measure in clinical studies of AOM.
BACKGROUND: Because resolution of symptoms is a primary goal of antimicrobial therapy in children with acute otitis media (AOM), measurement of symptoms in studies of antimicrobial effectiveness in such children is important. We have developed a scale for measuring symptoms of AOM in young children (AOM-SOS), and we present data on its construct validity and responsiveness. METHODS: We followed children 3 months to 3 years of age with AOM, who were receiving antimicrobial treatment, using the AOM-SOS scale. The scale was administered at the enrollment visit, as a twice-a-day diary measure, and at the follow-up visit (days 5-7). To evaluate construct validity, we examined the correlation, at entry, between AOM-SOS scores and scores on other measures of pain and functional status. To evaluate the scale's responsiveness, we examined the change in scale scores from entry to follow-up. We also examined the levels of agreement between the scale scores and overall assessments of the children by parents. RESULTS: We enrolled 70 children (mean age 12.5 months) of whom 57 returned for follow-up. The magnitude of the correlations between the AOM-SOS scale scores and other measures of pain and functional status ranged from 0.56 to 0.84. The responsiveness of the AOM-SOS, as measured by the standardized response mean was 1.20. CONCLUSIONS: These data support the validity and responsiveness of the AOM-SOS; the scale seems to measure effectively both pain and overall functional status in young children with AOM. Changes in score over the first few days of illness were substantial and generally matched the assessments both of parents and of clinicians. The AOM-SOS promises to be useful as an outcome measure in clinical studies of AOM.
Authors: Alejandro Hoberman; Jack L Paradise; Howard E Rockette; Nader Shaikh; Ellen R Wald; Diana H Kearney; D Kathleen Colborn; Marcia Kurs-Lasky; Sonika Bhatnagar; Mary Ann Haralam; Lisa M Zoffel; Carly Jenkins; Marcia A Pope; Tracy L Balentine; Karen A Barbadora Journal: N Engl J Med Date: 2011-01-13 Impact factor: 91.245
Authors: Alejandro Hoberman; Jack L Paradise; Howard E Rockette; Diana H Kearney; Sonika Bhatnagar; Timothy R Shope; Judith M Martin; Marcia Kurs-Lasky; Susan J Copelli; D Kathleen Colborn; Stan L Block; John J Labella; Thomas G Lynch; Norman L Cohen; MaryAnn Haralam; Marcia A Pope; Jennifer P Nagg; Michael D Green; Nader Shaikh Journal: N Engl J Med Date: 2016-12-22 Impact factor: 91.245
Authors: Nader Shaikh; Ellen R Wald; Jong-Hyeon Jeong; Marcia Kurs-Lasky; David Nash; Michael E Pichichero; Diana H Kearney; Mary Ann Haralam; A'Delbert Bowen; Lynda L Flom; Alejandro Hoberman Journal: J Pediatr Date: 2018-12-10 Impact factor: 4.406
Authors: Alejandro Hoberman; Jack L Paradise; Howard E Rockette; Jong-Hyeon Jeong; Diana H Kearney; Sonika Bhatnagar; Timothy R Shope; Gysella Muñiz; Judith M Martin; Marcia Kurs-Lasky; MaryAnn Haralam; Marcia A Pope; Jennifer P Nagg; Wenchen Zhao; Mohammad Kowser Miah; Jan Beumer; Raman Venkataramanan; Nader Shaikh Journal: Antimicrob Agents Chemother Date: 2017-06-27 Impact factor: 5.191
Authors: Annemarijn C Prins-van Ginkel; Marieke LA de Hoog; C Uiterwaal; Henriette A Smit; Patricia Cj Bruijning-Verhagen Journal: JMIR Mhealth Uhealth Date: 2017-11-28 Impact factor: 4.773
Authors: Respati W Ranakusuma; Amanda R McCullough; Eka D Safitri; Yupitri Pitoyo; Christopher B Del Mar; Elaine M Beller Journal: Pilot Feasibility Stud Date: 2018-09-10
Authors: Anne G M Schilder; Tasnee Chonmaitree; Allan W Cripps; Richard M Rosenfeld; Margaretha L Casselbrant; Mark P Haggard; Roderick P Venekamp Journal: Nat Rev Dis Primers Date: 2016-09-08 Impact factor: 52.329